What it's for (Indications)
- Imipramine hydrochloride, often known by its brand name Tofranil, is a tricyclic antidepressant (TCA) primarily indicated for the treatment of depressive illness.
- This includes both endogenous and reactive depression, and it is particularly effective in cases characterized by melancholia, apathy, and psychomotor retardation.
- Beyond its antidepressant effects, imipramine is also approved for the management of nocturnal enuresis (bedwetting) in children aged 6 years and older, particularly when organic causes have been thoroughly ruled out by a medical professional.
- Its use in children for enuresis is due to its anticholinergic effects on the bladder and its potential to alter sleep architecture.
- Clinical decision to prescribe imipramine must consider the risk-benefit profile, especially given the availability of newer antidepressant classes with potentially more favorable side effect profiles.
- Regular medical supervision and individualized treatment plans are paramount for its effective and safe utilization across all approved indications.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of imipramine must be meticulously individualized based on the patient's age, medical condition, and response to treatment, always under strict medical supervision. For adults with depression, treatment typically commences with a low dose, such as 25 mg taken three to four times daily, which is then gradually increased to an effective therapeutic range, usually between 75 mg and 150 mg daily, administered in divided doses or as a single bedtime dose. Doses exceeding 200 mg per day are generally reserved for hospitalized patients under close monitoring. In the elderly or adolescents, lower initial doses (e.g., 25-50 mg daily) are recommended due to increased sensitivity and potential for adverse effects, with gradual titration. For nocturnal enuresis in children aged 6 years and older, the typical initial dose is 25 mg taken one hour before bedtime. If an adequate response is not achieved after one week, the dose may be cautiously increased, not exceeding 50-75 mg daily depending on the child’s age and weight. Abrupt discontinuation should be avoided to prevent withdrawal symptoms; doses should be tapered gradually. |
Safety & Warnings
Common Side Effects
- Imipramine, being a tricyclic antidepressant, carries a range of potential side effects attributable to its diverse pharmacological actions, including anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
- Common anticholinergic side effects include dry mouth, blurred vision, constipation, urinary retention, and sinus tachycardia.
- Central nervous system effects can manifest as sedation, dizziness, tremors, headaches, and rarely, seizures or extrapyramidal symptoms.
- Cardiovascular effects are a significant concern and may include orthostatic hypotension, palpitations, and more seriously, arrhythmias (e.
- g.
- , QTc prolongation, heart block) and myocardial infarction, particularly in individuals with pre-existing cardiac disease.
- Psychiatric effects can include anxiety, agitation, insomnia, hypomania, or mania in susceptible individuals, especially those with undiagnosed bipolar disorder.
- Other potential adverse effects include weight gain, sweating, sexual dysfunction, gastrointestinal disturbances (nausea, vomiting), and hypersensitivity reactions.
- Patients should be closely monitored for the emergence of new or worsening symptoms throughout treatment.
Serious Warnings
- Black Box Warning: Antidepressants, including imipramine, increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with Major Depressive Disorder (MDD) and other psychiatric disorders. Imipramine is not approved for use in pediatric patients with MDD. Close monitoring for clinical worsening, suicidality, or unusual changes in behavior is essential, particularly during the initial phases of treatment and when doses are adjusted. Families and caregivers should be advised of the need for close observation and communication with the prescribing healthcare provider. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening suicidality (e.g., severe agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania), especially if these symptoms are severe, abrupt in onset, or not part of the patient’s presenting symptoms. The risk of suicide in adult patients with MDD may increase in the early stages of treatment.
- Imipramine warrants several significant warnings due to its pharmacological profile and potential for serious adverse events.
- Cardiovascular risks are paramount, including the potential for orthostatic hypotension, arrhythmias, myocardial infarction, and stroke; patients with pre-existing cardiovascular disease, especially recent myocardial infarction, require extreme caution and often specialist consultation.
- Imipramine can lower the seizure threshold, necessitating careful use in individuals with a history of epilepsy or other seizure disorders.
- Due to its anticholinergic effects, it should be used with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention.
- Psychiatric warnings include the potential for activation of mania or hypomania in individuals with bipolar disorder, and the risk of worsening depression or emergence of suicidal ideation and behavior, especially in young patients (see Black Box Warning).
- Abrupt discontinuation can lead to withdrawal symptoms such as nausea, headache, malaise, and flu-like symptoms; therefore, gradual tapering is crucial.
- Potential drug interactions are numerous and significant, including with monoamine oxidase inhibitors (MAOIs), other CNS depressants, anticholinergic agents, adrenergic agents, and drugs affecting cytochrome P450 enzymes, particularly CYP2D6.
- Close monitoring for these interactions is essential to prevent severe reactions like serotonin syndrome.
How it Works (Mechanism of Action)
Imipramine exerts its primary therapeutic effects by inhibiting the reuptake of norepinephrine and serotonin (5-hydroxytryptamine, 5-HT) into presynaptic nerve terminals in the central nervous system. By blocking these reuptake transporters, imipramine increases the concentrations of these crucial neurotransmitters in the synaptic cleft, thereby enhancing their postsynaptic receptor activation. This elevation in synaptic norepinephrine and serotonin is believed to underlie its antidepressant efficacy. Imipramine is metabolized in the liver to its active metabolite, desipramine, which is also a potent norepinephrine reuptake inhibitor, contributing significantly to its overall pharmacological action. Beyond its reuptake inhibition, imipramine also possesses considerable antagonist activity at various other receptors, including muscarinic cholinergic, alpha-1 adrenergic, and histamine H1 receptors. These additional receptor interactions are largely responsible for the anticholinergic (e.g., dry mouth, blurred vision), orthostatic hypotensive (alpha-1 blockade), and sedative (H1 blockade) side effects commonly associated with the drug.